ProQR Therapeutics N.V. PRQR
1.32 USD +0.06 (+4.76%)
Nov 12, 2026, 10:48 AM EST
1.25 Day range 1.34
1.20 52-week range 2.49
- YTD
- -34.65%
- 1 year
- -38.89%
News
benzinga.com ProQR Therapeutics Q3 EPS $(0.10) Beats $(0.11) Estimate, Sales $5.933M Beat $5.350M Estimate ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 9.09 percent increase over losses of…
benzinga.com ProQR Therapeutics To Present Data On Its AX-0810, AX-0811 At The Liver Meeting 2026, Nature Conferences RNA ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing…
benzinga.com HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Lowers Price Target to $8 HC Wainwright & Co. analyst Ananda Ghosh maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $12 to $8.
benzinga.com Coty Posts Mixed Q4 Results, Joins Wolfspeed, ATRenew And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures mixed, Nasdaq 100 up 0.1%. Coty Inc (COTY) shares down 7.7% after reporting losses in Q4 and exit of Gucci Beauty license.- benzinga.com B of A Securities Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target of $8 B of A Securities analyst Alec Stranahan initiates coverage on ProQR Therapeutics (NASDAQ:PRQR) with a Buy rating and announces Price Target of $8.
benzinga.com ProQR Therapeutics Q2 EPS $(0.09) Beats $(0.14) Estimate, Sales $10.183M Beat $5.560M Estimate ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.14) by 35.71 percent. This is a 25 percent increase over losses of…
benzinga.com Evercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6 Evercore ISI Group analyst Gavin Clark-Gartner maintains ProQR Therapeutics (NASDAQ:PRQR) with a Outperform and raises the price target from $5 to $6.
benzinga.com ON Semiconductor To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday Top analysts change outlook on top names: BMO, Chardan, Rosenblatt, Susquehanna, Evercore, Deutsche Bank, Baird, Stephens & Co.- benzinga.com Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $3 Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $4 to $3.
benzinga.com Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success ProQR reported positive AX-0810 Phase 1 data and raised $50 million, with Eli Lilly joining a concurrent share purchase.- benzinga.com ProQR Therapeutics Prices Registered Direct Offering Of 27,624,310 Shares At $1.81 Per Share For Total Gross Proceeds Of ~$50M; Also Enters Private Placement With Lilly For ~5.1M Shares At Same Offer Price ProQR Therapeutics N.V. (NASDAQ:PRQR) ("ProQR"), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing…
- benzinga.com ProQR Therapeutics Announces Data From Its Ongoing Phase 1 Clinical Study Of AX-0810 Investigational Axiomer RNA Editing Oligonucleotide; Sees Target Engagement On All Key Biomarkers Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the evaluable 3 mg/kg and 6 mg/kg cohortsAX-0810 demonstrated…
- benzinga.com ProQR Therapeutics Q1 EPS $(0.15), Inline, Sales $2.381M Miss $5.530M Estimate ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 50 percent decrease over losses of $(0.10) per share from the same…
- benzinga.com ProQR Therapeutics Collaborates With Ginkgo Bioworks Over Access To 50+ Instrument Autonomous Lab Nebula ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com ProQR Therapeutics Q4 EPS $(0.09) Misses $(0.08) Estimate, Sales $5.458M Miss $8.550M Estimate ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 10 percent increase over losses of…- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com ProQR Therapeutics Q3 EPS $(0.10), Inline, Sales $2.882M Miss $8.550M Estimate ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 9.09 percent increase over losses of $(0.11) per share from the…- benzinga.com Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $4 price target.
- benzinga.com ProQR Therapeutics Gets European Medicines Agency's Committee's Authorization For Clinical Trial Application For Phase 1 Trial Of AX-0810 To Treat Clerosing Cholangitis, Biliary Atresia ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $4 price target.
- benzinga.com ProQR Therapeutics Q2 EPS $(0.12) Misses $(0.09) Estimate, Sales $4.327M Miss $4.408M Estimate ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.09) by 39.53 percent. This is a 300 percent decrease over losses of…
benzinga.com ProQR Therapeutics Q2 EPS $(0.12) Misses $(0.09) Estimate ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.09) by 39.53 percent. This is a 300 percent decrease over losses of…
benzinga.com Cantor Fitzgerald Reiterates Overweight on ProQR Therapeutics, Maintains $8 Price Target Cantor Fitzgerald analyst Timur Ivannikov reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Overweight and maintains $8 price target.- benzinga.com JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $8 Price Target JMP Securities analyst Jonathan Wolleben reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Market Outperform and maintains $8 price target.
benzinga.com Oppenheimer Maintains Outperform on ProQR Therapeutics, Lowers Price Target to $9 Oppenheimer analyst Andreas Argyrides maintains ProQR Therapeutics (NASDAQ:PRQR) with a Outperform and lowers the price target from $15 to $9.- benzinga.com Evercore ISI Group Initiates Coverage On ProQR Therapeutics with Outperform Rating, Announces Price Target of $5 Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on ProQR Therapeutics (NASDAQ:PRQR) with a Outperform rating and announces Price Target of $5.
- benzinga.com ProQR Therapeutics Appoints Dennis Hom As CFO LEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies…
- benzinga.com Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $4 price target.
- benzinga.com HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Raises Price Target to $12 HC Wainwright & Co. analyst Andrew Fein maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and raises the price target from $10 to $12.
benzinga.com This Ralph Lauren Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - benzinga.com Jones Trading Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target of $11 Jones Trading analyst Catherine Novack initiates coverage on ProQR Therapeutics (NASDAQ:PRQR) with a Buy rating and announces Price Target of $11.
- benzinga.com JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $8 Price Target JMP Securities analyst Jonathan Wolleben reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Market Outperform and maintains $8 price target.
- benzinga.com Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $4 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $10 Price Target HC Wainwright & Co. analyst Andrew Fein reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $10 price target.
- benzinga.com ProQR Receives $9.1M to Develop RNA Therapy for Rett Syndrome, Impacting 350,000 People ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today…
- benzinga.com Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
- benzinga.com HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Raises Price Target to $10 HC Wainwright & Co. analyst Andrew Fein maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and raises the price target from $5 to $10.
- benzinga.com This First Solar Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
- benzinga.com Raymond James Upgrades ProQR Therapeutics to Strong Buy, Raises Price Target to $14 Raymond James analyst Steven Seedhouse upgrades ProQR Therapeutics (NASDAQ:PRQR) from Outperform to Strong Buy and raises the price target from $6 to $14.
- benzinga.com ProQR Therapeutics Commences Public Offering Of Its Ordinary Shares; No Terms Disclosed All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the offering amount in ordinary shares at the…
- benzinga.com CSX Posts Weak Earnings, Joins Lucid Group, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- benzinga.com Why TSMC Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
- benzinga.com ProQR Presents Its Axiomer RNA Editing Technology At RNA Editing Summit ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20,…
- benzinga.com Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $2.5 Price Target Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $2.5 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $5 Price Target HC Wainwright & Co. analyst Andrew Fein reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $5 price target.
- benzinga.com ProQR Gives Preclinical Proof Of Concept Data For AX-0810 Axiomer RNA Editing Program Targeting NTCP For Cholestatic Diseases ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing
- benzinga.com ProQR Therapeutics Says It Achieved Successful Defense of New Challenge To Its Axiomer IP Portfolio The company announced it has again successfully defended against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer. The opposition was filed in June 2021 with…